Sage Therapeutics Inc (SAGE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Date: November 9, 2018
Pages: 79
Price:
US$ 250.00
License [?]:
Publisher: GlobalData
Report type: Company Report
Delivery: E-mail Delivery (PDF)
ID: S953D0D3A97EN
Leaflet:

Download PDF Leaflet

Sage Therapeutics Inc (SAGE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Summary

Sage Therapeutics Inc (Sage) is a clinical-stage biopharmaceutical company that discovers and develops therapeutics and medicines for central nervous system (CNS) disorders. It develops drugs based on selective allosteric modulation of CNS synaptic and extrasynaptic receptors. The company has a portfolio of product candidates with the focus of being able to modulate two critical CNS receptor systems, NMDA and GABA. The company’s pipeline products include Brexanolone, SAGE-217, SAGE-324 and SAGE-718 compounds for use in treatment of indications such as postpartum depression, major depressive disorders, bipolar depression, Parkinson's disease, insomnia, epileptiform disorders and NMDA hypofunction. Sage is headquartered in Cambridge, Massachusetts, the US.

Sage Therapeutics Inc (SAGE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope
  • Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
  • Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
  • Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
  • Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
  • Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
  • Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
  • Business Description - A brief description of the company's operations.
  • Key Employees - A list of the key executives of the company.
  • Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
  • Key Competitors - A list of the key competitors of the company.
  • Key Recent Developments - A brief on recent news about the company.
Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
  • The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
  • The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
  • Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
  • The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
  • Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
  • Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company.

NOTE: Out of security concerns GlobalData requires using corporate email address.
Sage Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Sage Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018
Sage Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018
Sage Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018
Sage Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018
Sage Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details
Venture Financing
Sage Therapeutics Raises US$38 Million In Series C Venture Financing
Sage Therapeutics Raises US$10 Million In Venture Financing
Sage Therapeutics Raises US$20 Million In Series B Venture Financing
Sage Therapeutics Raises US$2.8 Million In Expanded Series A Financing Round
Partnerships
Sage Therapeutics and Shionogi Enter into Co-Development Agreement
Licensing Agreements
Sage Therapeutics Enters into Licensing Agreement with Ligand Pharma
Sage Therapeutics Enters into Licensing Agreement with University of California
Sage Therapeutics Enters Into Licensing Agreement With Washington University To Develop Gaba Receptor Small Molecules
Sage Therapeutics Amends Licensing Agreement with Regents of the University of California and University of California, Davis
Sage Therapeutics Amends Licensing Agreement with CyDex Pharma
Equity Offering
Sage Therapeutics Raises USD575 Million in Public Offering of Shares
Sage Therapeutics Raises USD345 Million in Public Offering of Shares
Sage Therapeutics Raises USD201 Million in Public Offering of Shares
Sage Therapeutics Raises USD150 Million in Public Offering of Shares
Sage Therapeutics Raises USD138 Million in Public Offering of Shares
Sage Therapeutics Raises USD103.5 Million in IPO
Sage Therapeutics Inc - Key Competitors
Sage Therapeutics Inc - Key Employees
Sage Therapeutics Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Financial Announcements
Aug 07, 2018: Sage therapeutics announces second quarter 2018 financial results and highlights pipeline and business progress
May 03, 2018: Sage Therapeutics Announces First Quarter 2018 Financial Results and Provides Update on Pipeline and Progress toward Launch Readiness
Feb 22, 2018: Sage Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results
Nov 02, 2017: Sage Therapeutics Announces Third Quarter 2017 Financial Results and Provides Pipeline Update
Aug 03, 2017: Sage Therapeutics Announces Second Quarter 2017 Financial Results and Provides Pipeline Update
May 09, 2017: Sage Therapeutics Announces First Quarter 2017 Financial Results and Provides Pipeline Update
Feb 23, 2017: Sage Therapeutics Announces Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update
Corporate Communications
Nov 08, 2017: Sage Therapeutics Appoints Asha Nayak, M.D., Ph.D., to Board of Directors
Jul 10, 2017: Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Apr 24, 2017: Sage Therapeutics Appoints Michael Cloonan as Chief Business Officer and Expands Executive Team
Product News
04/19/2017: Sage Therapeutics to Present at American Academy of Neurology 2017 Annual Meeting
02/07/2018: Sage Therapeutics Receives FDA Breakthrough Therapy Designation for SAGE-217 for the Treatment of Major Depressive Disorder
01/31/2018: Sage Therapeutics Announces Positive Results from Placebo-Controlled Trial in a Model of Insomnia Demonstrating Activity on Sleep Parameters and Supporting Development of SAGE-217 as Potential Treatment for Sleep Disorders
Product Approvals
May 30, 2018: Sage Therapeutics Announces FDA Acceptance of NDA Filing and Grant of Priority Review for Brexanolone IV in the Treatment of Postpartum Depression
Apr 23, 2018: Sage Therapeutics Submits New Drug Application to U.S. FDA for Intravenous Brexanolone in the Treatment of Postpartum Depression
May 18, 2017: Sage Therapeutics Receives Fast Track Designation for SAGE-217 for the Treatment of Major Depressive Disorder
Clinical Trials
Jun 12, 2018: Sage Announces Pivotal Phase 3 Trial Status for SAGE-217 in Major Depressive Disorder and Postpartum Depression based on FDA Breakthrough Therapy Meeting
Apr 17, 2018: Sage Therapeutics to Present Brexanolone Postpartum Depression Data at Upcoming Spring Medical Meetings
Apr 17, 2018: Sage Therapeutics to Present SAGE-217 Major Depressive Disorder Data at Upcoming Spring Medical Meetings
Dec 07, 2017: Sage Therapeutics Reports Positive Top-line Results from Phase 2 Placebo-Controlled Trial of SAGE-217 in Major Depressive Disorder
Nov 09, 2017: Sage Therapeutics Announces Brexanolone Achieves Primary Endpoints in Both Phase 3 Clinical Trials in Postpartum Depression
Sep 12, 2017: Sage Therapeutics Reports Top-Line Results from Phase 3 STATUS Trial of Brexanolone in Super-Refractory Status Epilepticus
Jul 11, 2017: Alzheimer’s Drug Discovery Foundation announces new grant for an innovative Allopregnanolone clinical trial
Jun 12, 2017: Sage Therapeutics Announces The Lancet Publishes Positive Phase 2 Brexanolone (SAGE-547) Clinical Data in Severe Postpartum Depression
Apr 19, 2017: Sage Therapeutics to Present on SAGE-217 at American Academy of Neurology 2017 Annual Meeting
Feb 13, 2017: Sage Therapeutics Advances SAGE-217 into Placebo-Controlled Phase 2 Clinical Trial in Major Depressive Disorder
Appendix
Methodology
About GlobalData
Contact Us
Disclaimer

LIST OF TABLES

Sage Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017
Sage Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Sage Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018
Sage Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018
Sage Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018
Sage Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018
Sage Therapeutics Raises US$38 Million In Series C Venture Financing
Sage Therapeutics Raises US$10 Million In Venture Financing
Sage Therapeutics Raises US$20 Million In Series B Venture Financing
Sage Therapeutics Raises US$2.8 Million In Expanded Series A Financing Round
Sage Therapeutics and Shionogi Enter into Co-Development Agreement
Sage Therapeutics Enters into Licensing Agreement with Ligand Pharma
Sage Therapeutics Enters into Licensing Agreement with University of California
Sage Therapeutics Enters Into Licensing Agreement With Washington University To Develop Gaba Receptor Small Molecules
Sage Therapeutics Amends Licensing Agreement with Regents of the University of California and University of California, Davis
Sage Therapeutics Amends Licensing Agreement with CyDex Pharma
Sage Therapeutics Raises USD575 Million in Public Offering of Shares
Sage Therapeutics Raises USD345 Million in Public Offering of Shares
Sage Therapeutics Raises USD201 Million in Public Offering of Shares
Sage Therapeutics Raises USD150 Million in Public Offering of Shares
Sage Therapeutics Raises USD138 Million in Public Offering of Shares
Sage Therapeutics Raises USD103.5 Million in IPO
Sage Therapeutics Inc, Key Competitors
Sage Therapeutics Inc, Key Employees
Sage Therapeutics Inc, Subsidiaries

LIST OF FIGURES

Sage Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Sage Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Sage Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Sage Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Sage Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Sage Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Sage Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Sage Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Skip to top


Ask Your Question

Sage Therapeutics Inc (SAGE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: